Last Update 20 Feb 26

KYMR: Future Atopic Dermatitis And Asthma Data Will Support Upside Potential

Analysts have slightly raised their price targets on Kymera Therapeutics, reflecting updated assumptions around discount rates, revenue growth, profit margins, and a very high future P/E that incorporate both the recent Overweight initiation at Barclays and the downgrade to Peer Perform at Wolfe Research.

Analyst Commentary

Recent research views on Kymera Therapeutics are mixed, with one firm initiating with a positive stance and another firm moving to a more neutral rating. Together, these calls highlight where analysts see upside potential and where they want to see more proof on execution.

Bullish Takeaways

Bullish analysts appear comfortable underwriting a very high future P/E, which signals confidence that Kymera could eventually grow into a premium valuation if its pipeline and business model perform in line with current expectations.
The Overweight initiation suggests that, at current levels, some analysts see an attractive risk reward tradeoff, with the current share price not fully reflecting Kymera’s longer term revenue potential.
Bullish views imply that recent assumptions around discount rates and profit margins are acceptable for a high risk biotech, which can support higher price targets even before full commercial visibility.
Supportive analysts seem to view near term volatility as acceptable in exchange for exposure to potential longer dated growth, which is consistent with the willingness to use ambitious long term valuation multiples.

Bearish Takeaways

The downgrade to Peer Perform signals that some analysts prefer to wait for clearer proof points on execution before assigning further upside, especially given the very high future P/E embedded in some models.
More cautious analysts appear concerned that expectations around future revenue and margin expansion may already be demanding, leaving less room for error if milestones or timelines do not materialize as assumed.
The move to a more neutral stance highlights sensitivity to changes in discount rates and risk assumptions, which can weigh on valuation for a company that is still heavily dependent on future outcomes.
Bearish analysts may see the current balance between potential upside and clinical or commercial risk as more evenly matched, leading them to step back from an Outperform call and treat Kymera as a hold rather than a clear source of excess returns.

What’s in the News

Kymera started dosing patients in the BREADTH Phase 2b trial of KT-621 in moderate to severe eosinophilic asthma. This is a 12 week, global, randomized, double blind, placebo controlled, dose ranging study in about 264 adults that is expected to inform Phase 3 dose selection across Type 2 indications (Key Developments).
The company outlined anticipated 2026 milestones for its oral immunology pipeline, including KT-621 in Phase 2 and partnered program KT-485/SAR447971 with Sanofi. A Phase 1 trial for the latter is expected to start in 2026 upon option exercise by Gilead for a separate collaboration program (Key Developments).
The FDA granted Fast Track designation to KT-621 for moderate to severe atopic dermatitis, giving Kymera access to more frequent FDA interactions and the potential for accelerated approval or priority review if criteria are met (Key Developments).
Kymera completed a follow on equity offering of common stock, raising about US$602m by selling 7,000,000 shares at a price of US$86 per share, following an earlier filing for a US$500m follow on equity offering of common stock (Key Developments).
Certain common stock, options, warrants and restricted stock units held by directors and officers are under a lock up agreement through 8 February 2026. This limits sales or transfers of these securities for 61 days starting 9 December 2025 without underwriter consent (Key Developments).

Valuation Changes

Fair Value: $116.71 is unchanged, indicating the model’s central valuation estimate remains the same.
Discount Rate: Discount Rate has fallen slightly from 7.12% to 7.06%, a modest reduction in the assumed risk level.
Revenue Growth: Revenue Growth assumptions now reflect a 3.83% decline instead of a 4.32% decline, implying a slightly less negative revenue outlook in the model.
Net Profit Margin: Profit Margin has eased from 16.96% to 16.15%, trimming the assumed long term profitability level.
Future P/E: Future P/E has risen slightly from a very large multiple to an even higher level, moving from 1,943x to 2,006x, which keeps the implied valuation multiple extremely elevated.

0 views

Key Takeaways

Advancing clinical programs and strategic partnerships could increase market share and positively impact future revenue and earnings.
Solid cash runway supports focused R&D investments, potentially boosting long-term growth without immediate financing pressures.
High R&D expenses and reliance on partnerships pose risks to Kymera's long-term financial health and ability to maintain a leadership position in their sector.

Catalysts

About Kymera Therapeutics

Together with its subsidiary, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.What are the underlying business or industry changes driving this perspective?

Kymera Therapeutics plans to advance its STAT6 and TYK2 programs into several clinical stages, which could potentially increase future revenue due to the expansion into new treatment markets and therapeutic areas.
The anticipated Phase II and III trials for their immunology pipeline aim to deliver biologics-like efficacy in oral form, which could enhance net margins by reducing manufacturing costs associated with biologics and potentially capturing a larger market share.
The collaboration with Sanofi on the IRAK4 program, with expanded Phase II trials, positions Kymera to fast-track toward pivotal trials, potentially accelerating time-to-market and impacting future earnings positively.
The company's strategy to introduce at least one new IND per year could expand their pipeline steadily, offering opportunities for revenue growth from licensing deals or partnerships.
With a significant cash runway extending into mid-2027, Kymera can support its R&D activities without immediate pressure for additional financing, allowing focused investment in high-potential programs that could drive long-term earnings growth.

Kymera Therapeutics Earnings and Revenue Growth

Kymera Therapeutics Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

Analysts are assuming Kymera Therapeutics's revenue will grow by 20.4% annually over the next 3 years.
Analysts are not forecasting that Kymera Therapeutics will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Kymera Therapeutics's profit margin will increase from -475.6% to the average US Biotechs industry of 15.9% in 3 years.
If Kymera Therapeutics's profit margin were to converge on the industry average, you could expect earnings to reach $13.0 million (and earnings per share of $0.17) by about May 2028, up from $-223.9 million today.
In order for the above numbers to justify the analysts price target, the company would need to trade at a PE ratio of 410.7x on those 2028 earnings, up from -9.8x today. This future PE is greater than the current PE for the US Biotechs industry at 20.4x.
Analysts expect the number of shares outstanding to grow by 5.84% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 6.47%, as per the Simply Wall St company report.

Kymera Therapeutics Future Earnings Per Share Growth

Risks

What could happen that would invalidate this narrative?

The transition to a video format for financial updates may not significantly impact investor perception or the company’s market value, and does not directly address any operational or financial performance issues.
Competition in the STAT6 space has increased, which may impact Kymera's ability to maintain its leadership position and could affect future revenue streams.
Although significant progress is being made with partners like Sanofi, reliance on partnerships exposes Kymera to risks if partners face challenges in advancing clinical trials, potentially impacting future earnings.
The financial performance shows high R&D expenses with $71.8 million spent in the fourth quarter alone, which could strain resources and impact net margins if new drugs don't reach successful commercialization.
Despite a significant cash balance, the projected cash runway into mid-2027 suggests that sustained high operational costs could pose a risk to long-term financial health if projected clinical milestones or revenue targets are not met.

Valuation

How have all the factors above been brought together to estimate a fair value?

The analysts have a consensus price target of $57.667 for Kymera Therapeutics based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $97.0, and the most bearish reporting a price target of just $41.0.
In order for you to agree with the analyst's consensus, you'd need to believe that by 2028, revenues will be $82.2 million, earnings will come to $13.0 million, and it would be trading on a PE ratio of 410.7x, assuming you use a discount rate of 6.5%.
Given the current share price of $33.69, the analyst price target of $57.67 is 41.6% higher.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Kymera Therapeutics?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

KYMR: Advancing Clinical Milestones Will Drive Meaningful Upside in Immunology Indications